|
1
|
Vascellari M, Capello K, Carminato A, Zanardello C, Baioni E and Mutinelli F: Incidence of mammary tumors in the canine population living in the Veneto region (Northeastern Italy): Risk factors and similarities to human breast cancer. Prev Vet Med. 126:183–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bird RC, DeInnocentes P, Church Bird AE, Lutful Kabir FM, Martinez-Romero EG, Smith AN and Smith BF: Autologous hybrid cell fusion vaccine in a spontaneous intermediate model of breast carcinoma. J Vet Sci. 20:e482019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mohammed SI, Meloni GB, Pinna Parpaglia ML, Marras V, Burrai GP, Meloni F, Pirino S and Antuofermo E: Mammography and ultrasound imaging of preinvasive and invasive canine spontaneous mammary cancer and their similarities to human breast cancer. Cancer Prev Res (Phila). 4:1790–1798. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdelmegeed SM and Mohammed S: Canine mammary tumors as a model for human disease. Oncol Lett. 15:8195–8205. 2018.PubMed/NCBI
|
|
5
|
Sanchez-Rangel E and Inzucchi SE: Metformin: Clinical use in type 2 diabetes. Diabetologia. 60:1586–1593. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN and Mantzoros CS: Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 60:1363–1371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cho SW, Yi KH, Han SK, Sun HJ, Kim YA, Oh BC, Park YJ and Park DJ: Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol. 393:24–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang T, Guo P, Zhang Y, Xiong H, Yu X, Xu S, Wang X, He D and Jin X: The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci. 14:24603–24618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W and Romero IL: Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 212:479.e1–479.e10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chai X, Chu H, Yang X, Meng Y, Shi P and Gou S: Metformin increases sensitivity of pancreatic cancer cells to gemcitabine by reducing CD133+ cell populations and suppressing ERK/P70S6K signaling. Sci Rep. 5:144042015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E and Udono H: Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA. 112:1809–1814. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Watanabe M, Yamamoto H, Eikawa S, Shien K, Shien T, Soh J, Hotta K, Wada J, Hinotsu S, Fujiwara T, et al: Study about the efficacy of metformin to immune function in cancer patients. Acta Med Okayama. 70:327–330. 2016.PubMed/NCBI
|
|
14
|
Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y and Zhao WL: Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 3:e2752012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han G, Gong H, Wang Y, Guo S and Liu K: AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther. 16:77–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kimball SR: Interaction between the AMP-activated protein kinase and mTOR signaling pathways. Med Sci Sports Exerc. 38:1958–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yue W, Yang CS, DiPaola RS and Tan XL: Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila). 7:388–397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bahrami A, Khazaei M, Hasanzadeh M, ShahidSales S, Joudi Mashhad M, Farazestanian M, Sadeghnia HR, Rezayi M, Maftouh M, Hassanian SM, et al: Therapeutic potential of targeting PI3K/AKT pathway in treatment of colorectal cancer: rational and progress. J Cell Biochem. 119:2460–2469. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schultze SM, Hemmings BA, Niessen M and Tschopp O: PI3K/AKT, MAPK and AMPK signalling: Protein kinases in glucose homeostasis. Expert Rev Mol Med. 14:e12012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Uyama R, Nakagawa T, Hong SH, Mochizuki M, Nishimura R and Sasaki N: Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. Vet Comp Oncol. 4:104–113. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin DH, Kim Y, Lee BB, Han J, Kim HK, Shim YM and Kim DH: Metformin induces cell cycle arrest at the G1 phase through E2F8 suppression in lung cancer cells. Oncotarget. 8:101509–101519. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie W, Wang L, Sheng H, Qiu J, Zhang D, Zhang L, Yang F, Tang D and Zhang K: Metformin induces growth inhibition and cell cycle arrest by upregulating MicroRNA34a in renal cancer cells. Med Sci Monit. 23:29–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Canavese M, Santo L and Raje N: Cyclin dependent kinases in cancer: Potential for therapeutic intervention. Cancer Biol Ther. 13:451–457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sfacteria A, Bertani C, Costantino G, Del Bue M, Paiardini M, Cervasi B, Piedimonte A and De Vico G: Cyclin D1 expression in pre-cancerous and cancerous lesions of the canine mammary gland. J Comp Pathol. 128:245–251. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Xu W, Yan Z, Zhao W, Mi J, Li J and Yan H: Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways. J Exp Clin Cancer Res. 37:632018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai X, Hu X, Tan X, Cheng W, Wang Q, Chen X, Guan Y, Chen C and Jing X: Metformin induced AMPK activation, G0/G1 phase cell cycle arrest and the inhibition of growth of esophageal squamous cell carcinomas in vitro and in vivo. PLoS One. 10:e01333492015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao S, Tan H, Zhu N, Gao H, Lv C, Gang J and Ji Y: Oridonin induces apoptosis through the mitochondrial pathway in human gastric cancer SGC-7901 cells. Int J Oncol. 48:2453–2460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiong ZS, Gong SF, Si W, Jiang T, Li QL, Wang TJ, Wang WJ, Wu RY and Jiang K: Effect of metformin on cell proliferation, apoptosis, migration and invasion in A172 glioma cells and its mechanisms. Mol Med Rep. 20:887–894. 2019.PubMed/NCBI
|
|
29
|
Sergeeva TF, Shirmanova MV, Zlobovskaya OA, Gavrina AI, Dudenkova VV, Lukina MM, Lukyanov KA and Zagaynova EV: Relationship between intracellular pH, metabolic co-factors and caspase-3 activation in cancer cells during apoptosis. Biochim Biophys Acta Mol Cell Res. 1864:604–611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M and Gotlieb WH: Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecol Oncol. 121:492–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li X, Li B, Ni Z, Zhou P, Wang B, He J, Xiong H, Yang F, Wu Y, Lyu X, et al: Metformin synergizes with BCL-XL/BCL-2 inhibitor ABT-263 to induce apoptosis specifically in p53-defective cancer cells. Mol Cancer Ther. 16:1806–1818. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park JH, Kim YH, Park EH, Lee SJ, Kim H, Kim A, Lee SB, Shim S, Jang H, Myung JK, et al: Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer. Cancer Sci. 110:2834–2845. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saeki K, Watanabe M, Tsuboi M, Sugano S, Yoshitake R, Tanaka Y, Ong SM, Saito T, Matsumoto K, Fujita N, et al: Anti-tumour effect of metformin in canine mammary gland tumour cells. Vet J. 205:297–304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB and Khaper N: Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One. 9:e982072014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen YH, Yang SF, Yang CK, Tsai HD, Chen TH, Chou MC and Hsiao YH: Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells. Mol Med Rep. 23:232021.PubMed/NCBI
|
|
37
|
Guo L, Cui J, Wang H, Medina R and Lin Y: Metformin enhances anti-cancer effect of cisplatin in meningioma through AMPK-mTOR signaling pathways. Mol Ther Oncolytics. 20:119–131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zakikhani M, Blouin MJ, Piura E and Pollak MN: Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 123:271–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dey N, De P and Leyland-Jones B: PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. Pharmacol Ther. 175:91–106. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Delgado L, Gärtner F and Dias Pereira P: Activation of mammalian target of rapamycin in canine mammary carcinomas: An immunohistochemical study. J Comp Pathol. 152:138–144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen YT, Tan KA, Pang LY and Argyle DJ: The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention. BMC Vet Res. 8:732012. View Article : Google Scholar : PubMed/NCBI
|
